Key result
Bioresorbable magnesium-zinc stents show early promise for transcatheter pulmonary valve replacement despite limited clinical evidence.
Why the study?
Patients with congenital heart disease often require repeated pulmonary valve interventions, where permanent metallic frames increase cumulative implant burden and complicate future treatment.
Answers are grounded in this paper and cite their sources.
Applying lessons from coronary bioresorbable stents, magnesium-zinc alloy bioresorbable frames offer a promising framework for future transcatheter pulmonary valve replacements to minimize long-term implant burden.
Bioresorbable stents (BRS) have been explored in cardiovascular intervention to provide temporary mechanical support while reducing long-term foreign material. The coronary experience has shown both the potential and the limitations of this strategy. First-generation polymeric stents demonstrated feasibility but were limited by thick struts, insufficient radial strength, delayed healing, and increased scaffold thrombosis. In contrast, metallic bioresorbable platforms improved mechanical performance, but each material system still faces trade-offs between strength, degradation rate, and biological response. Transcatheter pulmonary valve replacement (TPVR) may represent a clinically meaningful setting for renewed BRS development. Patients with congenital heart disease often require repeated pulmonary valve interventions over a lifetime, and permanent metallic frames may increase cumulative implant burden and complicate future treatment. However, TPVR imposes distinct requirements, including large-diameter expansion, stable anchoring, fatigue resistance, controlled degradation, and leaflet-frame integration. This review summarizes the lessons learned from coronary BRS, discusses material considerations for TPVR-oriented stent design, and evaluates current preclinical evidence for bioresorbable and regenerative pulmonary valve platforms. Particular attention is given to magnesium–zinc alloys as a tunable material strategy for future bioresorbable TPVR frames. Although direct evidence for fully bioresorbable metallic TPVR devices remains limited, this approach provides a rational framework for next-generation pulmonary valve intervention.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) conducted a review in Right ventricular outflow tract dysfunction / Congenital heart disease. Bioresorbable stents (BRS) vs. Permanent metallic stents was evaluated. Bioresorbable stents, particularly magnesium-zinc alloys, offer a promising framework for transcatheter pulmonary valve replacement, though direct clinical evidence remains limited.
Synapse has enriched 10 related papers. Consider them for comparative context: